Validation of Early Detection Ovarian Cancer Biomarkers (Team Project)

Abbreviated Name

OC Team 1

Lead Investigator

Skates, Steven — Massachusetts General Hospital

Coordinating Investigator

Skates, Steven — Massachusetts General Hospital

Involved Investigators

Abstact

Early detection of Ovarian Cancer (OC) is one of the key clinical problems in this disease. We propose a team EDRN project to address the issue of early detection of OC by performing a validation study on candidate protein markers already identified in previous EDRN research or in the literature (e.g. protein products of TCGA identified mutations specific to ovarian cancer). (See appendix for full listing) Biospecimen sources have been identified which include samples obtained at diagnosis and matched controls (Urban, Godwin, Marks, Skates), and longitudinal samples obtained prior to diagnosis (Urban, Skates, Godwin). Bioinformatic filters will be applied to rank the candidates (Diamandis). In order of ranking, candidate proteins for which high quality antibodies are available will be measured by development of ELISAs at JHU (Chan/Zhang) or through NAPPA at DFCI (Anderson/LaBaer), while for other candidates mass spectrometry based selective reaction monitoring (SRM) assays will be developed at PNNL (Rodland). Three milestones are defined. The first two milestones are to assemble the necessary specimens and to develop the qualifying assay(s). The final milestone is to estimate the markers’ sensitivity one year prior to diagnosis at a given high specificity.

Aims

1. Rank candidates identified through past research using bioinformatic analyses (GO, KEGG, Ingenuity), including cancer pathway analyses and gene ontology classifications. 2. Attempt to develop assays for top ranked candidates from step 1 with goal of assay development for 50 candidates (using multiplex immunoassays where high quality mAb pairs or mAb/pAb pairs exist, and SRM targeted mass spec for all other candidates) 3. “Rule in” at least 10 and at most 25 candidates based on assay performance in serum biospecimens obtained at diagnosis, achieving minimal clinical sensitivity (> 5%) at 98% specificity. 4. Measure in pooled samples most proximal to diagnosis of ovarian cancer case in screening study, and in matched control samples, minimizing pooling to achieve minimum required volume for SRM in depleted serum. 5. Rank candidates by sensitivity at fixed high specificity 6. Measure up to top 25 candidates from step 5 in individual longitudinal samples from ovarian cancer cases in screening study, and in matched control samples 7. Candidates validated for early detection of ovarian cancer if clinical sensitivity achieved (5% or greater) at 98% specificity at least 1 year prior to clinical detection.

Analytic Method

ELISAs, NAPPA and mass spectrometry based selective reaction monitoring (SRM)

Publications

No publications available at this time for this protocol.

Biomarkers

Data Collections

No data collections available at this time for this protocol.

Team Project

Start Date

Aug 1 2011

Estimated Finish Date

Jul 31 2014

Protocol ID

330

Protocol Type

Collaboration

Field of Research

Proteomics

Collaborative Group

Breast and Gynecologic Cancers Research Group

Cancer Types

Malignant neoplasm of ovary

Phased Status